RT Journal Article SR Electronic T1 Fairness and efficiency considerations in COVID-19 vaccine allocation strategies: a case study comparing front-line workers and 65-74 year olds in the United States JF medRxiv FD Cold Spring Harbor Laboratory Press SP 2022.02.03.22270414 DO 10.1101/2022.02.03.22270414 A1 Rumpler, Eva A1 Feldman, Justin M. A1 Bassett, Mary T. A1 Lipsitch, Marc YR 2022 UL http://medrxiv.org/content/early/2022/09/28/2022.02.03.22270414.abstract AB The COVID-19 epidemic in the United States has been characterized by two stark disparities. COVID-19 burden has been unequally distributed among racial and ethnic groups and at the same time the mortality rates have been sharply higher among older age groups. These disparities have led some to suggest that inequalities could be reduced by vaccinating front-line workers before vaccinating older individuals, as older individuals in the US are disproportionately Non-Hispanic White.We compare the performance of two distribution policies, one allocating vaccines to front-line workers and another to older individuals aged 65-74-year-old. We estimate both the number of lives saved and the number of years of life saved under each of the policies, overall and in every race/ethnicity groups, in the United States and every state.We show that prioritizing COVID-19 vaccines for 65-74-year-olds saves both more lives and more years of life than allocating vaccines front-line workers in each racial/ethnic group, in the United States as a whole and in nearly every state. When evaluating fairness of vaccine allocation policies, the overall benefit to impact of each population subgroup should be considered, not only the proportion of doses that is distributed to each subgroup. Further work can identify prioritization schemes that perform better on multiple equity metrics.Competing Interest StatementEva Rumpler has no conflicts of interest to disclose. Justin Feldman reports grants to institution from the Robert Wood Johnson Foundation and payments from the New York City Department of Health & Mental Hygiene and employment by the Center for Policing Equity. Mary Bassett reports grants to institution from the Robert Wood Johnson Foundation. Marc Lipsitch reports grants from CDC, grants from NIH, grants from UK NIHR, grants from Pfizer, personal fees from Merck, personal fees from Janssen, personal fees from Sanofi Pasteur, personal fees from Bristol Myers Squibb, personal fees from Peter Diamandis/Abundance Platinum, outside the submitted work; and unpaid advice to One Day Sooner, Pfizer, Janssen, Astra-Zeneca, COVAX (United Biomedical). Funding StatementER and ML were supported by the Morris-Singer Fund. This work was supported in part by Award Number U01CA261277 from the US National Cancer Institute of the National Institutes of Health. The content of this article is solely the responsibility of the authors and does not necessarily represent the official views of the Morris-Singer Fund or the National Institutes of Health. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study involves only openly available data obtained from the American Community Survey (ACS) and the National Center for Health Statistics (NCHS), which can be obtained from https://data.cdc.gov/NCHS/Deaths-involving-coronavirus-disease-2019-COVID-19/ks3g-spdg, https://data.cdc.gov/NCHS/NVSS-Provisional-COVID-19-Deaths-by-Place-of-Death/4va6-ph5s, and https://www.census.gov/programs-surveys/acs/data.html.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThis study involves only openly available data obtained from the American Community Survey (ACS) and the National Center for Health Statistics (NCHS), which can be obtained from https://data.cdc.gov/NCHS/Deaths-involving-coronavirus-disease-2019-COVID-19/ks3g-spdg, https://data.cdc.gov/NCHS/NVSS-Provisional-COVID-19-Deaths-by-Place-of-Death/4va6-ph5s, and https://www.census.gov/programs-surveys/acs/data.html. https://data.cdc.gov/NCHS/Deaths-involving-coronavirus-disease-2019-COVID-19/ks3g-spdg https://data.cdc.gov/NCHS/NVSS-Provisional-COVID-19-Deaths-by-Place-of-Death/4va6-ph5s https://www.census.gov/programs-surveys/acs/data.html